Lung Cancer

FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC

February 16th 2021, 7:00pm

Article

The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.

Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show

February 16th 2021, 6:30pm

Article

A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.

Possible Treatment Identified for Aggressive NSCLC Subset

February 16th 2021, 6:00pm

Article

Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.

Lung Cancer Screenings Fall, Biopsy Rates Rise During COVID-19

February 15th 2021, 10:15pm

Article

Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.

FDA Grants Tiragolumab Breakthrough Therapy Designation for PD-L1–High NSCLC

February 15th 2021, 6:30pm

Article

Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.

What We’re Reading: More Americans Vaccinated Than Infected; US Funds Rapid OTC COVID-19 Tests; Breast Most Common Cancer Worldwide

February 2nd 2021, 3:33pm

Article

More Americans have received at least 1 dose of a coronavirus disease 2019 (COVID-19) vaccine than have tested positive for the virus; Biden administration funds mass production of a rapid over-the-counter COVID-19 test; breast cancer surpasses lung cancer as most common cancer worldwide.

First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC

January 23rd 2021, 3:30pm

Article

Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable.

Study Finds No Association Between Autoimmune Disease and Lung Cancer Survival

January 14th 2021, 10:00pm

Article

Patients with both lung cancer and autoimmune disease have no significant difference in survival than patients with lung cancer alone, according to recent research from Northwestern University.

ACS Cancer Statistics Report Shows Record Drop in Cancer Mortality, But Persistent Disparities

January 13th 2021, 9:00pm

Article

The 2021 American Cancer Society annual Cancer Statistics report found that the overall rate of cancer mortality continuously declined from 1991 to 2018 but also highlighted racial and geographic disparities.

Joanna Thompson Discusses What Makes a Patient High Risk for Lung Cancer

December 31st 2020, 2:00pm

Video

There are several risk factors to review when determining whether or not a patient is high risk for lung cancer and should be screened, said Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.